Università de Roma La Sapienza-ko ikertzaileekin lankidetzan egindako argitalpenak (65)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Gliomatosis cerebri in children: A poor prognostic phenotype of diffuse gliomas with a distinct molecular profile

    Neuro-oncology, Vol. 26, Núm. 9, pp. 1723-1737

2023

  1. Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance

    Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  3. ORC1 binds to cis-transcribed RNAs for efficient activation of replication origins

    Nature Communications, Vol. 14, Núm. 1

  4. Protective ileostomy creation after anterior resection of the rectum: Shared decision-making or still subjective?

    Colorectal Disease, Vol. 25, Núm. 4, pp. 647-659

2022

  1. 30-day morbidity and mortality of sleeve gastrectomy, Roux-en-Y gastric bypass and one anastomosis gastric bypass: a propensity score-matched analysis of the GENEVA data

    International Journal of Obesity, Vol. 46, Núm. 4, pp. 750-757

  2. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high–grade non-muscle-invasive urothelial bladder cancer

    Urologic Oncology: Seminars and Original Investigations, Vol. 40, Núm. 11, pp. 491.e11-491.e19

  3. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  4. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions

    Gut, Vol. 71, Núm. 8, pp. 1669-1683

  5. Definition and Diagnostic Criteria for Sarcopenic Obesity: ESPEN and EASO Consensus Statement

    Obesity Facts, Vol. 15, Núm. 3, pp. 321-335

  6. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement

    Clinical Nutrition, Vol. 41, Núm. 4, pp. 990-1000

  7. HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples

    British Journal of Cancer, Vol. 126, Núm. 12, pp. 1783-1794

  8. Organoselenium compounds as functionalizing agents for gold nanoparticles in cancer therapy

    Colloids and Surfaces B: Biointerfaces, Vol. 219

  9. Robotic oncologic colorectal surgery with a new robotic platform (CMR Versius): hope or hype? A preliminary experience from a full-robotic case-series

    Techniques in Coloproctology, Vol. 26, Núm. 9, pp. 745-753

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Bringing onco‐innovation to Europe’s healthcare systems: The potential of biomarker testing, real world evidence, tumour agnostic therapies to empower personalised medicine

    Cancers, Vol. 13, Núm. 3, pp. 1-12

  3. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  4. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382